ADC Therapeutics SA has announced its intention to redomicile from Switzerland to Delaware, a strategic move aimed at improving long-term shareholder value and operational alignment with its U.S. operations. This decision comes as part of a broader trend in the pharmaceutical industry, where companies are increasingly seeking to benefit from the favorable corporate laws and regulatory environments in the United States.

The company’s board of directors unanimously approved the proposal, which will be presented to shareholders at an extraordinary general meeting scheduled for 2027. The redomiciliation is expected to provide several advantages, including reducing corporate regulatory obligations and costs, enhancing the company’s ability to attract investors, and increasing its comparability to peers.

Background

ADC Therapeutics SA, classified under the SIC code 2834 for Pharmaceutical Preparations, is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with hematological malignancies and solid tumors. The company’s common shares are currently traded on the New York Stock Exchange under the ticker symbol ADCT.

Recent filings include an S-4 on November 3, 2026, which outlines the redomiciliation plans, as well as a Schedule 13G and an 8-K filed in late October 2026, indicating ongoing corporate activities and shareholder communications.

What the Filing Says

The S-4 filing details the company’s plan to transition to a corporation incorporated under the laws of Delaware, which will be named ADC Therapeutics, Inc. The filing states, “Our board of directors believes that the Redomiciliation Transaction will enhance long-term shareholder value by providing various benefits.”

Among the benefits highlighted are reduced regulatory obligations, increased alignment with U.S. operations, and enhanced flexibility under Delaware corporate law, which is known for its business-friendly environment.

Impact

This redomiciliation may significantly affect ADC Therapeutics' shareholders, as it will alter their rights under Delaware corporate law compared to Swiss law. The transition is designed to strengthen the company’s position in the competitive pharmaceutical landscape, potentially making it more attractive to investors and facilitating future capital raises.

What's Next

The next steps include the extraordinary general meeting where shareholders will vote on the proposals outlined in the filing. If approved, the redomiciliation is expected to be completed as soon as practicable following the meeting, contingent upon meeting all conditions outlined in the proxy statement/prospectus.

As ADC Therapeutics moves forward with this strategic initiative, it will be essential for stakeholders to stay informed about the implications of the redomiciliation and how it may impact the company’s operations and market position.